Inhibikase Therapeutics

What Inhibikase Therapeutics does

Inhibikase Therapeutics, Inc. (NASDAQ: IKT) is a clinical-stage biopharmaceutical company developing small-molecule prodrug therapies, with lead asset IKT-001 — a prodrug of imatinib mesylate — currently in Phase 3 development for Pulmonary Arterial Hypertension (PAH), an orphan indication. The company is running the IMPROVE-PAH trial, a 486-patient study across approximately 180 sites in 16 countries, and received FDA alignment in December 2025 on an accelerated Phase 3 pathway. The proprietary prodrug platform re-engineers known kinase inhibitors to improve delivery and tolerability, and the pipeline was expanded in February 2025 through the ~$14.8M acquisition of CorHepta Pharmaceuticals. Inhibikase is headquartered in Atlanta, Georgia, operates with 11-50 employees, and was incorporated in Delaware in 2020 with origins traceable to 2008.

The company's revenue model is not yet active: it is pre-revenue with no approved product, no licensing royalties, and no disclosed collaboration revenue. Future revenue mechanics will depend on one of three paths — direct commercialization of IKT-001 in PAH, out-licensing or partnership deals, or expansion of IKT-001 (or CorHepta-derived assets) into additional indications. To fund clinical operations, the company has executed multiple equity raises totaling approximately $228M between January 2023 and November 2025, including a $110M private placement in October 2024 led by Soleus Capital and a $100M public offering in November 2025. Cash reserves stood at approximately $178.8M at year-end 2025 and $170.4M in Q1 2026, with FY2025 net loss of $48.3M reflecting heavy R&D and organizational investment.

Recent strategic shifts indicate a transition from pure R&D to commercial readiness: a new CEO (Mark Iwicki, a biotech industry veteran) and a Chief Commercial and Strategy Officer (Timothy Pigot) have been appointed. Customer-facing operations are not yet relevant because no product is marketed; instead, the company engages with clinical investigators across 16 countries to execute the Phase 3 program. The combination of orphan designation, accelerated regulatory pathway alignment, multi-region clinical footprint, and a strengthened balance sheet positions Inhibikase as a single-asset-focused PAH play with a runway extending through key Phase 3 milestones.

Name

Inhibikase Therapeutics

Legal name

Inhibikase Therapeutics, Inc.

Website

https://inhibikase.com

Company type

Public

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Inhibikase Therapeutics is a clinical-stage biopharmaceutical company developing prodrug therapies, with lead asset IKT-001 (a prodrug of imatinib mesylate) in Phase 3 trials for Pulmonary Arterial Hypertension (PAH), targeting an orphan indication across multiple countries.

Ownership category

akta.pro rank

Product category

Pulmonary Arterial Hypertension Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Pulmonary Hypertension & Rare Pulmonary Disease Therapies (HLAIAIAG)

akta.pro secondary industries

Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF), Respiratory & Allergy Pharmaceuticals (HLAIAAAH)

Keywords

• Kinase inhibitor therapeutics
• Pulmonary hypertension treatment
• Prodrug pharmaceutical development
• Small molecule therapeutics
• Cardiopulmonary drug development

Headquarters

HQ city

Atlanta

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Product Sales: Pre-revenue clinical-stage pharmaceutical company. If IKT-001 for Pulmonary Arterial Hypertension receives regulatory approval, the company would generate revenue through product sales to healthcare providers and patients. PAH is an orphan indication affecting approximately 50,000 Americans.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Inhibikase Therapeutics is a clinical-stage pharmaceutical company developing small molecule kinase inhibitor therapeutics, with its lead product candidate IKT-001 (a prodrug of imatinib mesylate) in a global Phase 3 IMPROVE-PAH trial for the treatment of Pulmonary Arterial Hypertension. The candidate targets aberrant signaling through type III receptor tyrosine kinases including platelet derived growth factor receptors and c-Kit to address pulmonary vascular remodeling. The company is pre-revenue and is funded through equity financings and prior grants.

Product overview

Inhibikase Therapeutics is a clinical-stage pharmaceutical company developing small molecule kinase inhibitor therapeutics to treat cardiopulmonary diseases, primarily Pulmonary Arterial Hypertension (PAH). The company's lead product candidate is IKT-001, a prodrug of imatinib mesylate, which has been advanced to a pivotal Phase 3 clinical trial (IMPROVE-PAH). IKT-001 is designed to address pulmonary vascular remodeling by inhibiting type III receptor tyrosine kinases. The company was previously focused on Parkinson's disease and related disorders but has shifted its primary focus to PAH.

Differentiator

Problem solved

Functional benefit

Products and services

• IKT-001 IKT-001 is a prodrug of imatinib mesylate being developed as a treatment for Pulmonary Arterial Hypertension (PAH). It targets aberrant signaling through type III receptor tyrosine kinases including platelet derived growth factor receptors and c-Kit. The candidate is in Phase 3 clinical development under the IMPROVE-PAH study.

Quantifiable outcome

• Safety readout expected H1 2027, PVR analysis mid-2028, 6MWD assessment mid-2029, potential approval late 2030
• +2 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators15 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• United Therapeutics: Established leader in PAH with multiple approved therapies (Tyvaso, Remodulin, Orenitram). Directly relevant as the dominant commercial player in the same indication Inhibikase is targeting, providing both a market validation reference and a competitive benchmark.
• Bayer (riociguat / Adempas): Major pharmaceutical company marketing Adempas (riociguat), the first FDA-approved drug specifically for chronic thromboembolic pulmonary hypertension (CTEPH) and an approved PAH therapy. Relevant as a large-pharma incumbent with an approved PAH asset and global commercial reach.
• Johnson & Johnson (Opsumit / macitentan): Markets Opsumit (macitentan), an endothelin receptor antagonist approved for PAH. Relevant as a large-pharma incumbent with a major established PAH franchise and global commercialization capability.

Direct peers

• Aerovate Therapeutics: Clinical-stage PAH-focused company developing AV-101 (inhaled imatinib) for pulmonary arterial hypertension. Most directly comparable peer given the same active moiety (imatinib) and same target indication, differing primarily in delivery route and formulation strategy.
• Liquidia Technologies: Commercial-stage PAH company with YUTREPIA (inhaled treprostinil) approved and additional programs in development. Comparable as a focused PAH competitor targeting the same prescriber base with both approved and investigational assets.
• Gossamer Bio: Clinical-stage biopharmaceutical company with seralutinib (inhaled PDGF receptor/c-Kit/KIT kinase inhibitor) in development for PAH. Highly comparable given shared PDGF/c-Kit mechanism targeting in the same PAH indication, representing a mechanistically similar competitive approach.
• Tenax Therapeutics: Late clinical-stage company developing levosimendan (TNX-103) for pulmonary hypertension with focus on PH-HFpEF and related indications. Comparable as a small-cap clinical-stage company targeting pulmonary vascular disease with a single late-stage asset.

Emerging players

• Insmed: Late clinical-stage biopharmaceutical company developing therapies for serious pulmonary and rare diseases, including brensocatib for bronchiectasis. Comparable as a pulmonary-focused mid-cap with late-stage clinical assets and orphan/rare disease orientation.
• Keros Therapeutics: Clinical-stage biotech developing therapeutics targeting TGF-β superfamily for hematological and cardiopulmonary disorders, including pulmonary hypertension programs. Comparable as a small-cap clinical-stage company developing kinase/signaling-modulating therapeutics for cardiopulmonary indications.

Others

• Acceleron Pharma (acquired by Merck): Was a clinical-stage biopharmaceutical company developing sotatercept for PAH (acquired by Merck for $11.5B in 2021). Relevant as a precedent of large-pharma M&A for a late-stage PAH asset, signaling potential acquirer interest in the space.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/inhibikase-therapeutics
• Xx.com/inhibikase
• Facebookfacebook.com/Inhibikase

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds12 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Inhibikase Therapeutics